Patients
A new and innovative way to improve patients’ recoveries following colorectal surgery.
Professionals
An innovative solution for the protection of digestive anastomosis.
Patient Benefits
Clinical
Colovac is a colorectal anastomosis protection device designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery.
The Company
Established in 2015 and based in France, SafeHeal is a clinical stage medical device manufacturer. Specializing in the development of anastomosis protection devices for colorectal surgery, SafeHeal’s premier device, Colovac, was invented to eliminate the need for diverting ostomies in patients undergoing colectomy.
Testimonials
Leading colorectal surgeons are talking about the benefits of Colovac.
Dr. Antonio D’Urso
Digestive surgery and bariatric at Hôpitaux Universitaires de Strasbourg, France
Read More"In order to always improve the quality of life of our patients, our hospital has agreed to be part of the clinical study. I am a huge advocate of the Colovac: it enables avoidance of diverting stoma, it is minimally invasive and fully reversible at any time."
Prof. Jérémie Lefevre
General Surgery at Hôpital Saint-Antoine, Paris-France
Read More“The preliminary clinical trial results indicate that Colovac is an alternative to ileostomy, obviating the burden of stoma care for patients with a rectal cancer.”
Dr. Patricia Sylla
Colon and Rectal Surgery at Mount Sinai, New York-USA
Read More"There is a clinical need, Colovac’s approaching the problem from a different angle. For the patient, there is an immediate added value: avoiding an ostomy, it is an added value, no matter what."
Recent News
SafeHeal® Closes Oversubscribed €35 Million Series C Equity Financing
Breakthrough device promises significantly improved patient recovery after colorectal surgery.
Read MoreSafeHeal Receives Breakthrough Device designation for Colovac Endoluminal Bypass Sheath
Breakthrough device promises significantly improved patient recovery after colorectal surgery.
Read More- SafeHeal Receives Breakthrough Device designation for Colovac Endoluminal Bypass Sheath: Click here to read the press release
- Chief Executive Officer Chris Richardson to Speak at LSI Emerging Medtech Summit: Click here to read the announcement
- SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer: Click here to read the press release
- SafeHeal Announces Successful Launch of IDE Study for Colovac Endoluminal Bypass Sheath: Click here to read the press release
1 Colovac is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.
V9.1_05012025